Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease

International Journal of Cardiology

Volumn 166, Issue 1, 2013, Pages 147-151

  Torp Pedersen, Christian ^a   Camm, A John ^b   Butterfield, Noam N ^c   Dickinson, Garth ^c   Beatch, Gregory N ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Cardiome Pharma Corp   (Canada)

Author keywords

Antiarrhythmics; Atrial fibrillation; Cardioversion; Ischemic heart disease; Vernakalant

Indexed keywords

PLACEBO; VERNAKALANT;

ADULT; ARTICLE; BRADYCARDIA; CARDIOVERSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NAUSEA; PARESTHESIA; PATIENT MONITORING; PRIORITY JOURNAL; QRS PROLONGATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINUS RHYTHM; SNEEZING; TREATMENT OUTCOME;

AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84877733730     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.108     Document Type: Article

References (20)

1. P.R. Kowey, R.A. Marinchak, S.J. Rials, and R.A. Filart Acute treatment of atrial fibrillation Am J Cardiol 81 1998 16C 22C
2. A. Wakai, and J.O. O'Neill Emergency management of atrial fibrillation Postgrad Med J 79 2003 313 319
3. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol 48 2006 e149 e246
4. J.A. Reiffel Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter Am Heart J 135 1998 551 556
5. T. Rudo, and P. Kowey Atrial fibrillation: choosing an antiarrhythmic drug Curr Cardiol Rep 8 2006 370 376
6. D. Fedida, P.M. Orth, and J.Y. Chen The mechanism of atrial antiarrhythmic action of RSD1235 J Cardiovasc Electrophysiol 16 2005 1227 1238
7. P. Dorian, A. Pinter, I. Mangat, V. Korley, S.S. Cvitkovic, and G.N. Beatch The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans J Cardiovasc Pharmacol 50 2007 35 40
8. D. Fedida, P.M. Orth, J.C. Hesketh, and A.M. Ezrin The role of late INa and antiarrhythmic drugs in EAD formation and termination of Purkinje fibers J Cardiovasc Electrophysiol 17 2006 S71 S78
9. P.R. Kowey, P. Dorian, L.B. Mitchell Atrial Arrhythmia Conversion Trial Investigators Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial Circ Arrhythm Electrophysiol 2 2009 652 659
10. D. Roy, C.M. Pratt, C. Torp-Pedersen for the Atrial Arrhythmia Conversion Trial Investigators Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial Circulation 117 2008 1518 1525
11. D. Roy, B.H. Rowe, I.G. Stiell for the CRAFT Investigators A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J Am Coll Cardiol 44 2004 2355 2361
12. C.M. Pratt, D. Roy, C. Torp-Pedersen for the Atrial Arrhythmia Conversion Trial (ACT-III) Investigators Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation Am J Cardiol 106 2010 1277 1283
13. I.G. Stiell, J.S. Roos, K.M. Kavanagh, and G. Dickinson A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm Am Heart J 159 2010 1095 1101
14. A.J. Camm Safety considerations in the pharmacological management of atrial fibrillation Int J Cardiol 127 2008 299 306
15. F. Er, O. Aslan, and E. Caglayan Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study Clin Res Cardiol 99 2010 369 373
16. R. Schilling Cardioversion of atrial fibrillation and the use of antiarrhythmic drugs Heart 96 2009 333 338
17. O.D. Pedersen, H. Bagger, N. Keller, B. Marchant, L. Kober, and C. Torp-Pedersen Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigation of arrhythmia and mortality on dofetilide (diamond) substudy Circulation 104 2001 292 296
18. N.G. Boyle, and K. Shivkumar Atrial fibrillation in congestive heart failure: current management Cardiol Clin 27 2009 79 93
19. J.T. VanderLugt, T. Mattioni, and S. Denker Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery Circulation 100 1999 369 375
20. P.E. Vardas, G.E. Kochiadakis, N.E. Igoumenidis, A.M. Tsatsakis, E.N. Simantirakis, and G.I. Chlouverakis Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study Chest 117 2000 1538 1545